Targeted Therapies for Glioma Stem Cells

S. J. Sundar; J. Wright; J. K. Hseih; A. E. Sloan

doi:10.1016/B978-0-12-803892-5.00018-8

Targeted Therapies for Glioma Stem Cells

S. J. Sundar, J. Wright, J. K. Hseih, A. E. Sloan

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Glioblastoma (GBM) is both the most common primary malignant brain tumor and the most fatal. While GBM exhibits many mechanisms of treatment resistance, many of these may be attributed to cancer stem cells (CSCs), a subpopulation of intratumor cells that possess inherent properties of self-renewal, proliferation, and ability to develop into heterogeneous tumors. Thus, therapies targeting CSCs could potentially advance GBM treatments and result in improved outcomes. Clinical trials currently underway that target CSCs include small molecule inhibitors of signaling pathways, microenvironment inhibitors, and dendritic cell vaccines. The results of these trials will guide future treatments of GBM.

Original language	English (US)
Title of host publication	Cancer Stem Cells
Subtitle of host publication	Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance
Publisher	Elsevier Inc.
Pages	459-471
Number of pages	13
ISBN (Electronic)	9780128039342
ISBN (Print)	9780128038925
DOIs	https://doi.org/10.1016/B978-0-12-803892-5.00018-8
State	Published - Sep 1 2016
Externally published	Yes

Keywords

Cancer stem cells
Clinical trial
Glioblastoma
Glioma stem cells
Targeted therapy

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/B978-0-12-803892-5.00018-8

Cite this

@inbook{43441cd1ae1744cd9c7f341486a98cce,

title = "Targeted Therapies for Glioma Stem Cells",

abstract = "Glioblastoma (GBM) is both the most common primary malignant brain tumor and the most fatal. While GBM exhibits many mechanisms of treatment resistance, many of these may be attributed to cancer stem cells (CSCs), a subpopulation of intratumor cells that possess inherent properties of self-renewal, proliferation, and ability to develop into heterogeneous tumors. Thus, therapies targeting CSCs could potentially advance GBM treatments and result in improved outcomes. Clinical trials currently underway that target CSCs include small molecule inhibitors of signaling pathways, microenvironment inhibitors, and dendritic cell vaccines. The results of these trials will guide future treatments of GBM.",

keywords = "Cancer stem cells, Clinical trial, Glioblastoma, Glioma stem cells, Targeted therapy",

author = "Sundar, {S. J.} and J. Wright and Hseih, {J. K.} and Sloan, {A. E.}",

year = "2016",

month = sep,

day = "1",

doi = "10.1016/B978-0-12-803892-5.00018-8",

language = "English (US)",

isbn = "9780128038925",

pages = "459--471",

booktitle = "Cancer Stem Cells",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Targeted Therapies for Glioma Stem Cells

AU - Sundar, S. J.

AU - Wright, J.

AU - Hseih, J. K.

AU - Sloan, A. E.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Glioblastoma (GBM) is both the most common primary malignant brain tumor and the most fatal. While GBM exhibits many mechanisms of treatment resistance, many of these may be attributed to cancer stem cells (CSCs), a subpopulation of intratumor cells that possess inherent properties of self-renewal, proliferation, and ability to develop into heterogeneous tumors. Thus, therapies targeting CSCs could potentially advance GBM treatments and result in improved outcomes. Clinical trials currently underway that target CSCs include small molecule inhibitors of signaling pathways, microenvironment inhibitors, and dendritic cell vaccines. The results of these trials will guide future treatments of GBM.

AB - Glioblastoma (GBM) is both the most common primary malignant brain tumor and the most fatal. While GBM exhibits many mechanisms of treatment resistance, many of these may be attributed to cancer stem cells (CSCs), a subpopulation of intratumor cells that possess inherent properties of self-renewal, proliferation, and ability to develop into heterogeneous tumors. Thus, therapies targeting CSCs could potentially advance GBM treatments and result in improved outcomes. Clinical trials currently underway that target CSCs include small molecule inhibitors of signaling pathways, microenvironment inhibitors, and dendritic cell vaccines. The results of these trials will guide future treatments of GBM.

KW - Cancer stem cells

KW - Clinical trial

KW - Glioblastoma

KW - Glioma stem cells

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85017542086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017542086&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-803892-5.00018-8

DO - 10.1016/B978-0-12-803892-5.00018-8

M3 - Chapter

AN - SCOPUS:85017542086

SN - 9780128038925

SP - 459

EP - 471

BT - Cancer Stem Cells

PB - Elsevier Inc.

ER -

Targeted Therapies for Glioma Stem Cells

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this